Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.45 |
| ▸ | P2RY12 | Q9H244 | 3/20 | 0.40 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
| ▸ | GAPDH | P04406 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14062513 | 1.00 | TYMP (0.45) | TYMPP2RY12ADORA2AADORA2BGAPDH | |
| SCHEMBL14063335 | 1.00 | TYMP (0.45) | TYMPP2RY12ADORA2AADORA2BGAPDH | |
| SCHEMBL3822659 | 0.92 | TYMP (0.47) | TYMPP2RY12ADORA2AADORA2B | |
| SCHEMBL21577261 | 0.90 | TYMP (0.46) | TYMPP2RY12ADORA2AADORA2B | |
| SCHEMBL21043925 | 0.90 | TYMP (0.48) | TYMPP2RY12ADORA2AADORA2B | |
| SCHEMBL16310642 | 0.89 | TYMP (0.45) | TYMPP2RY12 | |
| SCHEMBL17911711 | 0.89 | TYMP (0.45) | TYMPP2RY12ADORA2AADORA2B | |
| SCHEMBL22984001 | 0.89 | TYMP (0.58) | TYMPP2RY12 | |
| SCHEMBL21044306 | 0.89 | TYMP (0.58) | TYMPP2RY12 | |
| SCHEMBL3824088 | 0.89 | TYMP (0.58) | TYMPP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9409952-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2016-08-09 | — | — | US | disclosed |
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2015-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150080549-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | VIP, NGLY1, GLP1R | TYMP 2728/4885P2RY12 3130/4885ADORA2A 4792/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.